Top

Published in:

01-06-2010 | Original Article

Circulating tumour-derived microvesicles in plasma of gastric cancer patients

Authors: Jaroslaw Baran, Monika Baj-Krzyworzeka, Kazimierz Weglarczyk, Rafal Szatanek, Maria Zembala, Jakub Barbasz, Antoni Czupryna, Antoni Szczepanik, Marek Zembala

Published in: Cancer Immunology, Immunotherapy | Issue 6/2010

Abstract

Cell membrane microfragments called microvesicles (MV) originating from different cells are circulating in the blood of healthy subjects and their elevated numbers are found in different diseases, including cancer. This study was designed to characterise MV present in plasma of gastric cancer patients. Since majority of MV in blood are platelets-derived (PMV), plasma samples deprived of PMV were used. In comparison to control, the number of MV in patients was significantly elevated in all stages, higher in more advanced disease. Patients’ MV showed an increased membrane expression of CCR6 and HER-2/neu. The proportion of MV carrying some leucocyte determinants was low and similar in patients and control. Transmission electron microscopy showed their substantial heterogeneity in size and shape. The size determined by dynamic light scattering analysis confirmed this heterogeneity. The MV size distribution in patients was broader within the range of 10–800 nm, while in control MV showed 3-mode distribution within the range of 10–400 nm. Atomic force microscopy confirmed MV size heterogeneity with implication that larger objects represented aggregates of smaller microparticles. Patients’ MV exhibited increased absolute values of zeta potential, indicating a higher surface charge. Tumour markers HER-2/neu, MAGE-1, c-MET and EMMPRIN were detected both in control and patients’ samples with stronger expression in the latter. Significantly higher expression of MAGE-1 and HER-2/neu mRNA was observed in individual patients. All together, it suggests that at least some MV in plasma of gastric cancer patients are tumour-derived. However, their role in cancer requires further studies.

Available only for authorised users

Théry C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2:569–579PubMed

Taylor DD, Gerçel-Taylor C (2005) Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 92:305–311PubMed

Castellana D, Zobairi F, Martinez MC, Panaro MA, Mitolo V, Freyssinet JM, Kunzelmann C (2009) Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis. Cancer Res 69:785–793CrossRefPubMed

Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ (1999) Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 94:3791–3798PubMed

Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Branski P, Ratajczak MZ, Zembala M (2006) Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 55:808–818CrossRefPubMed

Taylor DD, Black PH (1986) Shedding of plasma membrane fragments. Neoplastic and developmental importance. Dev Biol 3:33–57

Ginestra A, Miceli D, Dolo V, Romano FM, Vittorelli ML (1999) Membrane vesicles in ovarian cancer fluids: a new potential marker. Anticancer Res 19:3439–3445PubMed

Poste G, Nicolson GL (1980) Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. Proc Natl Acad Sci USA 77:399–403CrossRefPubMed

Choi DS, Lee JM, Park GW, Lim HW, Bang JY, Kim YK, Kwon KH, Kwon HJ, Kim KP, Gho YS (2007) Proteomic analysis of microvesicles derived from human colorectal cancer cells. J Proteome Res 6:4646–4655CrossRefPubMed

10.

Wieckowski E, Whiteside TL (2006) Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol Res 36:247–254CrossRefPubMed

11.

Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Zembala M (2007) Tumour-derived microvesicles modulate biological activity of human monocytes. Immunol Lett 113:76–82CrossRefPubMed

12.

Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ (2005) Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 113:752–760CrossRefPubMed

13.

Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ (2006) Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 20:1487–1495CrossRefPubMed

14.

Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, Kim S (2003) Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastatic predictor. Eur J Cancer 39:184–191CrossRefPubMed

15.

Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL (2005) Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 11:1010–1020PubMed

16.

Taylor DD, Gercel-Taylor C, Gall SA (1996) Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies. J Soc Gynecol Invest 3:289–294CrossRef

17.

Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C (2005) Exosomal-like vesicles are present in human blood plasma. Int Immunol 17:879–887CrossRefPubMed

18.

Fujimi S, Ogura H, Tanaka H, Koh T, Hosotsubo H, Nakamori Y, Kuwagata Y, Shimazu T, Sugimoto H (2002) Activated polymorphonuclear leukocytes enhance production of leukocyte microparticles with increased adhesion molecules in patients with sepsis. J Trauma 52:443–448CrossRefPubMed

19.

Horstman LL, Jy W, Jimenez JJ, Ahn YS (2004) Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 9:1118–1135CrossRefPubMed

20.

Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK (2002) Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 106:2442–2447CrossRefPubMed

21.

Kanazawa S, Nomura S, Kuwana M, Muramatsu M, Yamaguchi K, Fukuhara S (2003) Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer. Lung Cancer 39:145–149CrossRefPubMed

22.

Brodsky SV, Facciuto ME, Heydt D, Chen J, Islam HK, Kajstura M, Ramaswamy G, Aguero-Rosenfeld M (2008) Dynamics of circulating microparticles in liver transplant patients. J Gastrointestin Liver Dis 17:261–268PubMed

23.

Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, Zaccheddu A, Colone M, Arancia G, Gentile M, Seregni E, Valenti R et al (2005) Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 128:1796–1804CrossRefPubMed

24.

Martínez-Lorenzo MJ, Anel A, Alava MA, Piñeiro A, Naval J, Lasierra P, Larrad L (2004) The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 295:315–329CrossRefPubMed

25.

Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L (2006) Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 66:9290–9298CrossRefPubMed

26.

Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L (2008) Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 15:80–88CrossRefPubMed

27.

Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L (2007) Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 67:2912–2915CrossRefPubMed

28.

Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR (2003) Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res 63:4331–4337PubMed

29.

Chaput N, Schartz NE, Andre F, Zitvogel L (2003) Exosomes for immunotherapy of cancer. Adv Exp Med Biol 532:215–221PubMed

30.

Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3–15CrossRefPubMed

31.

Sobin LH, Wittekind C (2002) TNM classification of malignant tumours, 6th edn. Wiley, Hoboken

32.

Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, Ross GD (2003) β-Glucan functions as a adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 63:9023–9031PubMed

33.

Szatanek R, Drabik G, Baran J, Kolodziejczyk P, Kulig J, Stachura J, Zembala M (2008) Detection of isolated tumour cells in the blood and bone marrow of patients with gastric cancer by combined sorting, isolation and determination of MAGE-1, -2 mRNA expression. Oncol Rep 19:1055–1060PubMed

34.

Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J, Jensen RT (2002) HER-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 62:3702–3710PubMed

35.

Piccin A, Murphy WG, Smith OP (2007) Circulating microparticles: pathophysiology and clinical implications. Blood Rev 21:157–171CrossRefPubMed

36.

Simak J, Gelderman MP (2006) Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 20:1–26CrossRefPubMed

37.

Pituch-Noworolska A, Drabik G, Szatanek R, Białas M, Kołodziejczyk P, Szczepanik A, Stachura J, Zembala M (2007) Immunophenotype of isolated tumour cells in the blood, bone marrow and lymph nodes of patients with gastric cancer. Pol J Pathol 58:93–97PubMed

38.

Ghadjar P, Loddenkemper C, Coupland SE, Stroux A, Noutsias M, Thiel E, Christoph F, Miller K, Scheibenbogen C, Keilholz U (2008) Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. J Cancer Res Clin Oncol 134:1181–1189CrossRefPubMed

39.

Rubie C, Oliveira-Frick V, Rau B, Schilling M, Wagner M (2006) Chemokine receptor CCR6 expression in colorectal liver metastasis. J Clin Oncol 24:5173–5174CrossRefPubMed

40.

Sugasawa H, Ichikura T, Tsujimoto H, Kinoshita M, Morita D, Ono S, Chochi K, Tsuda H, Seki S, Mochizuki H (2008) Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol 97:445–450CrossRefPubMed

41.

Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, Inoue H, Mori M (2002) Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 62:2937–2941PubMed

42.

Schimanski CC, Galle PR, Moehler M (2008) Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World J Gastroenterol 14:4721–4728CrossRefPubMed

43.

Lee HJ, Kim SW, Kim HY, Li S, Yun HJ, Song KS, Kim S, Jo DY (2009) Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer. Int J Oncol 34:473–480PubMed

44.

Gelderman MP, Simak J (2008) Flow cytometric analysis of cell membrane microparticles. Methods Mol Biol 484:79–93CrossRefPubMed

45.

Tadros TF (2007) General principles of colloid stability and the role of surface forces. In: Tadros TF (ed) Colloid stability part I. Viley-VCH Verlag GmbH, Weinheim

46.

Adamczyk Z, Zembala M, Michna A (2006) Polyelectrolyte adsorption layers studied by streaming potential and particle deposition. J Colloid Interface Sci 303:353–364CrossRefPubMed

47.

Jansa R, Sustar V, Frank M, Susanj P, Bester J, Mancek-Keber M, Krzan M, Iglic A (2008) Number of microvesicles in peripheral blood and ability of plasma to induce adhesion between phospholipid membranes in 19 patients with gastrointestinal diseases. Blood Cells Mol Dis 41:124–132CrossRefPubMed

Title: Circulating tumour-derived microvesicles in plasma of gastric cancer patients
Authors: Jaroslaw Baran
Monika Baj-Krzyworzeka
Kazimierz Weglarczyk
Rafal Szatanek
Maria Zembala
Jakub Barbasz
Antoni Czupryna
Antoni Szczepanik
Marek Zembala
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0808-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2010

Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells

Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008

Acknowledgement

IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo

Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma

Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer